Innoviva (INVA) Current Deferred Revenue (2010 - 2026)
Innoviva (INVA) posted Current Deferred Revenue of $3.7 million for Q1 2026, down 13.89% on a QoQ basis from $4.3 million in Q4 2025, and up 266.97% year-over-year from $1.0 million in Q1 2025.
Innoviva (INVA) Current Deferred Revenue (2010 - 2026) Analysis & Trends
Innoviva's Current Deferred Revenue history runs 13 years deep, the most recent figure standing at $3.7 million for Q1 2026.
- Quarterly Current Deferred Revenue rose 266.97% year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 million (up 266.97% YoY) and the FY2025 annual result came in at $4.3 million, up 279.22% from the prior year.
- Current Deferred Revenue was $3.7 million for Q1 2026 at Innoviva, down from $4.3 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $13.6 million in Q3 2025 and bottomed at $717000.0 in Q3 2024.
- A 5-year average of $2.8 million and a median of $2.1 million in 2022 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2024 — Current Deferred Revenue sank 73.72% — and 2025, when it soared 1792.75%.
- Innoviva's Current Deferred Revenue stood at $2.1 million in 2022, then tumbled by 39.02% to $1.3 million in 2023, then retreated by 11.82% to $1.1 million in 2024, then jumped by 279.22% to $4.3 million in 2025, then retreated by 13.89% to $3.7 million in 2026.
- Business Quant data shows INVA's Current Deferred Revenue at $3.7 million in Q1 2026, $4.3 million in Q4 2025, and $13.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Innoviva | 1.57 Bn | 969.11 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.68 Mn |
| Dec 31, 2025 | 4.27 Mn |
| Sep 30, 2025 | 13.57 Mn |
| Jun 30, 2025 | 3.13 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 1.13 Mn |
| Sep 30, 2024 | 717,000.00 |
| Jun 30, 2024 | 855,000.00 |
| Mar 31, 2024 | 987,000.00 |
| Dec 31, 2023 | 1.28 Mn |
| Sep 30, 2023 | 1.55 Mn |
| Jun 30, 2023 | 3.25 Mn |
| Mar 31, 2023 | 2.09 Mn |
| Dec 31, 2022 | 2.09 Mn |
| Sep 30, 2022 | 2.85 Mn |
| Sep 30, 2017 | 885,000.00 |
| Jun 30, 2017 | 885,000.00 |
| Mar 31, 2017 | 885,000.00 |
| Dec 31, 2016 | 885,000.00 |
| Sep 30, 2016 | 885,000.00 |